Metformina + Vildagliptina Azevedos

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Azevedos, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels. GNH USA supplies Metformina + Vildagliptina Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways. - Type 2 diabetes mellitus: improves glycaemic control when used alone or with other antidiabetic agents. - Inadequate control on metformin monotherapy: provides additional glucose‑lowering effect as part of combination therapy. - Patients requiring combination therapy: offers a single‑pill regimen that simplifies dosing and enhances adherence.

Adverse reactions may occur with Metformina + Vildagliptina use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Headache: mild cranial discomfort. - Upper respiratory tract infection: cold‑like symptoms. - Abdominal discomfort: cramping or pain. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring emergency care. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: worsening kidney function.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks. - Renal function: assess creatinine clearance; avoid in severe renal impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Cardiovascular status: evaluate for heart failure, as metformin may accumulate. - Pregnancy and lactation: discuss risks with the prescriber; generally avoided unless benefits outweigh risks. - Concomitant medications: review for drugs that affect renal clearance or increase hypoglycaemia risk. - Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and light.

Metformina + Vildagliptina can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vildagliptin exposure. - Insulin or sulfonylureas: heighten risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may raise plasma metformin levels. - ACE inhibitors or ARBs: can affect renal function, requiring dose adjustment. - Beta‑blockers: may mask hypoglycaemia symptoms.